BACKGROUND: Ipilimumab has been shown to improve overall survival in @entity1 with @entity320 ; however, complete responses (CRs) are uncommon. Immune-related side effects usually involve the skin or gastrointestinal tract. Neurologic events occur less frequently but are well described. CASE REPORT: We report the case of a 58-year-old @entity1 with @entity320 who commenced ipilimumab post spinal decompression and radiation. He developed a colitis post cycle 2 and ipilimumab was discontinued. Imaging, however, documented a radiological CR. 8 weeks later, he developed @entity451 and a @entity4685 despite an ongoing radiological CR. @entity134 use resulted in some improvement radiologically, without clinical improvement. CONCLUSION: We report @entity4685 with consequent @entity451 as a potential neurological immune-related side effect of ipilimumab. We further describe a @entity1 with a CR after 2 cycles of ipilimumab in the setting of radiation.    2014 S. Karger GmbH, Freiburg.

Late-onset XXXX after complete response to two cycles of ipilimumab for @entity320 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['Steroid'] @entity451 :: ('MESH:C536857', 'Disease') :: ['paraplegia'] @entity320 :: ('MESH:D008545', 'Disease') :: ['metastatic melanoma'] @entity4685 :: ('MESH:D009187', 'Disease') :: ['myelitis']
@entity451 :: (MESH:C536857,Disease) :: ['paraplegia']
